The depletion of serine beta‐lactamase‐like protein (LACTB) ameliorates metabolic dysfunction–associated steatotic liver disease by reducing ubiquitin‐mediated degradation of carnitine palmitoyltransferase 2

Documenti analoghi

• Characterization of brain morphology associated with metabolic dysfunction‐associated steatotic liver disease in the UK Biobank
  di: Wenxiao Fan, et al.
  Pubblicazione: (2025)
• Non‐invasive diagnosis of metabolic dysfunction‐associated steatotic liver disease: Current status, challenges, and future directions
  di: Yuqing Ma, et al.
  Pubblicazione: (2025)
• Glycaemic control metrics and metabolic dysfunction–associated steatotic liver disease in children and adolescents with type 1 diabetes
  di: Claudio Maffeis, et al.
  Pubblicazione: (2024)
• An interpretable machine learning model for predicting metabolic dysfunction‐associated steatotic liver disease in patients with type 2 diabetes
  di: Zhuolin Zhou, et al.
  Pubblicazione: (2025)
• Caution in interpreting imaging‐based rankings in network meta‐analyses of metabolic dysfunction–associated steatotic liver disease therapies
  di: Seoung Hoon Kim
  Pubblicazione: (2026)